Remove Clinical Research Remove Demo Remove Pharma Companies
article thumbnail

FDA Poised to Make Impact on Underrepresented Populations in Clinical Studies

H1 Blog

The recent draft by the FDA introduces additional guidelines for Diversity Action Plans aimed at improving diversity in clinical research. We’re curious to see what will happen over the next 12 months and how pharma companies will respond.” Find out more by requesting a demo today.

FDA 59
article thumbnail

Four Ideas for Pharma to Maximize the Influence of Digital Opinion Leaders in Medicine

H1 Blog

Insights for Thought Leading Stakeholder Engagement to Decrease Medication Non-Adherence Pharmaceutical companies have long recognized the importance of engaging key opinion leaders (KOLs) to gain insight and support for clinical research, drug development, and medical education.